Get the Stockscreener App
5.27
4.77%
0.24
Aptevo Therapeutics Inc stock is traded at $5.27, with a volume of 27,994.
It is up +4.77% in the last 24 hours and up +19.23% over the past month.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.
See More
Previous Close:
$5.03
Open:
$5.01
24h Volume:
27,994
Relative Volume:
0.18
Market Cap:
$6.31M
Revenue:
$12.99M
Net Income/Loss:
$-27.45M
P/E Ratio:
-0.00296
EPS:
-1779.0561
Net Cash Flow:
$-25.59M
1W Performance:
+23.13%
1M Performance:
+19.23%
6M Performance:
-81.35%
1Y Performance:
-98.48%
1-Day Range:
$5.01
$5.4096
1-Week Range:
$4.1801
$5.4096
52-Week Range:
$3.80
$486.00
Aptevo Therapeutics Inc Stock (APVO) Company Profile
Name
Aptevo Therapeutics Inc
Sector
Industry
Phone
206-838-0500
Address
2401 4TH AVE., SEATTLE, WA
Compare APVO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APVO
Aptevo Therapeutics Inc
|
5.34 | 5.94M | 12.99M | -27.45M | -25.59M | -1,779.06 |
VRTX
Vertex Pharmaceuticals Inc
|
438.33 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
746.43 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
839.34 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
334.74 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.85 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Aptevo Therapeutics Inc Stock (APVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-05-18 | Initiated | Ladenburg Thalmann | Buy |
| Oct-05-17 | Resumed | Piper Jaffray | Overweight |
Aptevo Therapeutics Inc Stock (APVO) Latest News
Risk On: Is Aptevo Therapeutics Inc impacted by rising ratesPortfolio Update Report & AI Driven Price Forecasts - baoquankhu1.vn
Aptevo Therapeutics (APVO) upgraded to buy: Here's why - MSN
Aug Chart Watch: What is Aptevo Therapeutics Incs valuation compared to sector2026 Reactions & Smart Money Movement Tracker - baoquankhu1.vn
Aug Swings: Is The Honest Company Inc stock risky to hold nowMarket Movement Recap & Real-Time Stock Entry Alerts - baoquankhu1.vn
Aptevo Therapeutics (APVO) Raised to Buy: Discover the Reasons - Bitget
Aptevo Therapeutics (APVO) Upgraded to Buy: Here's Why - Yahoo Finance
Tech Rally: Is Aptevo Therapeutics Inc impacted by rising rates2026 Sector Review & Real-Time Chart Breakout Alerts - baoquankhu1.vn
APVO Forecast, Price Target & Analyst Ratings | APTEVO THERAPEUTICS INC (NASDAQ:APVO) - ChartMill
APVO Should I Buy - Intellectia AI
APVO Technical Analysis & Stock Price Forecast - Intellectia AI
Update Recap: Can Aptevo Therapeutics Inc sustain its profitabilityMarket Movers & Risk Managed Investment Signals - baoquankhu1.vn
Institution Moves: Will IBEX outperform during market ralliesWeekly Risk Summary & Smart Allocation Stock Tips - baoquankhu1.vn
Nasdaq Moves: What are Aptevo Therapeutics Incs recent SEC filings showing2026 Buyback Activity & Expert Curated Trade Setups - baoquankhu1.vn
Risk Report: Is Aptevo Therapeutics Inc impacted by rising rates2026 Price Targets & AI Enhanced Trade Execution Alerts - baoquankhu1.vn
Roth MKM Maintains Aptevo Therapeutics(APVO.US) With Buy Rating, Maintains Target Price $21 - Moomoo
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate in Frontline AML Trial - citybuzz -
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment - NewMediaWire
Aptevo's Mipletamig Shows 86% Clinical Benefit Rate In Frontline AML As Emerging Data Demonstrate Additive Benefit To Standard Of Care Treatment | Corporate - EQS News
User - The Chronicle-Journal
Aptevo Rises on AML Data—But Will It Hold? - Bitget
Aptevo Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
10-K - sec.gov
Aptevo Therapeutics 10-K: Net loss $25.97M, EPS $(87.27) - TradingView
Aptevo Therapeutics (NASDAQ: APVO) outlines bispecific cancer pipeline and AML data - Stock Titan
[8-K] Aptevo Therapeutics Inc. Reports Material Event - Stock Titan
APVO Achieves Significant Advances in Clinical Pipeline and Capi - GuruFocus
Aptevo Provides State of the Business Report and 2025 Financial Results - Bitget
No CRS in 28 AML patients as Aptevo adds 3 CD3 drug candidates - Stock Titan
APVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Aptevo Therapeutics Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | AP81 | US03835L5049 - marketscreener.com
Aptevo Therapeutics Inc.: Fundamental Analysis and Financial Ratings | APVO | US03835L4059 - marketscreener.com
Aptevo to Participate in March 2026 Conferences - ACCESS Newswire
Aptevo sends incoming CEO to Roth, spotlights trispecific drugs in Lisbon - Stock Titan
Hedge Fund Moves: Whats next for Aptevo Therapeutics Inc stock2026 AllTime Highs & Smart Investment Allocation Insights - baoquankhu1.vn
Aptevo Therapeutics implements 1-for-18 reverse stock split - MSN
Pharma News: Is GeoVax Labs Inc Equity Warrants ROE strong enough2026 Stock Rankings & Weekly High Conviction Ideas - baoquankhu1.vn
Aptevo shares drop despite encouraging AML trial results - MSN
Aptevo’s Mipletamig Shows 86% Clinical Benefit Rate With No CRS in Frontline AML, Promising Safety and Efficacy Data 1 - Minichart
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Aptevo Reports Promising Interim Data for AML Therapy - TipRanks
Aptevo Therapeutics: Mipletamig Shows 86% Clinical Benefit Rate with No CRS in Frontline AML - TradingView
Aptevo Therapeutics Inc Announces New Interim Data For Mipletamig In Combination With Venetoclax And Azacitidine - marketscreener.com
Aptevo Therapeutics (APVO) reports 86% benefit, no CRS in mipletamig AML data - Stock Titan
Aptevo Therapeutics (APVO) Reveals Promising Results in AML Tria - GuruFocus
Aptevo Lists Lower on New Developments - Baystreet.ca
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Aptevo Therapeutics stock tumbles despite positive trial data - Investing.com India
Aptevo Therapeutics stock tumbles despite positive trial data By Investing.com - Investing.com UK
Aptevo Therapeutics Inc Stock (APVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.80%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):